UK Life Sciences Industrial Strategy Is Starting To Show Its Value In The Medtech Arena
Executive Summary
UK strategies that have sought to maximize the partnership potential of medtech innovators and the country's National Health Service have often not lasted long enough to prove their worth. But Neil Mesher, Philips CEO of UK and Ireland, says the Life Sciences Industrial Strategy might just be different.
You may also be interested in...
UK Plugs Into ‘Golden Period’ For Medtech Innovation
The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.
UK Life-Sciences Sector Deal Brings Life And Funding To Industrial Strategy
The next step in the UK government's life-science strategy, the Life Sciences Sector Deal, was issued today, setting out a blueprint of government-support mechanisms and private investment across the whole of the sector. The deal, signaled yesterday at UK HealthTech 2017, seeks to maximize the potential of medtech and pharma businesses, and exploit the value of the NHS.
Moonshot Projects In Life Sciences Strategy Can Lift UK Over Brexit Hurdle
The long-awaited UK Life Sciences Strategy, part of the industrial strategy proposed after the May government took office in summer 2016, was released today. With input from major medtech organizations and UK-based pharma groups it charts a course ahead for the £64bn national life-sciences industry as the UK seeks to embrace its post-EU future.